NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis $5.92 +0.72 (+13.83%) Closing price 03:59 PM EasternExtended Trading$5.94 +0.02 (+0.35%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Altimmune Stock (NASDAQ:ALT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Altimmune alerts:Sign Up Key Stats Today's Range$5.36▼$6.0550-Day Range$5.20▼$7.4552-Week Range$5.14▼$11.16Volume11.36 million shsAverage Volume3.05 million shsMarket Capitalization$455.85 millionP/E RatioN/ADividend YieldN/APrice Target$20.83Consensus RatingModerate Buy Company OverviewAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Read More… Remove Ads Altimmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreALT MarketRank™: Altimmune scored higher than 51% of companies evaluated by MarketBeat, and ranked 694th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAltimmune has only been the subject of 3 research reports in the past 90 days.Read more about Altimmune's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Altimmune are expected to grow in the coming year, from ($1.35) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Altimmune's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.77% of the float of Altimmune has been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Altimmune has recently decreased by 3.56%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted31.77% of the float of Altimmune has been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Altimmune has recently decreased by 3.56%, indicating that investor sentiment is improving. News and Social Media1.7 / 5News Sentiment0.06 News SentimentAltimmune has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Altimmune this week, compared to 8 articles on an average week.Search Interest32 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $52,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Stock News HeadlinesStifel Nicolaus Keeps Their Buy Rating on Altimmune (ALT)March 14 at 1:32 PM | markets.businessinsider.comEvercore bullish on Altimmune, likes drug move into alcohol related diseaseMarch 14 at 1:32 PM | markets.businessinsider.comEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… They’re studying something far more alien… Something you’ve never seen before…March 14, 2025 | Paradigm Press (Ad)Piper Sandler Reaffirms Their Buy Rating on Altimmune (ALT)March 14 at 8:31 AM | markets.businessinsider.comAltimmune (ALT) Gets a Hold from William BlairMarch 14 at 8:31 AM | markets.businessinsider.comAltimmune to test obesity drug for alcohol use disorder and related health conditionsMarch 13 at 5:26 PM | reuters.comHC Wainwright Estimates Altimmune's Q2 Earnings (NASDAQ:ALT)March 7, 2025 | americanbankingnews.comAltimmune to Host Virtual R&D Day on March 13, 2025March 6, 2025 | globenewswire.comSee More Headlines ALT Stock Analysis - Frequently Asked Questions How have ALT shares performed this year? Altimmune's stock was trading at $7.21 at the beginning of the year. Since then, ALT shares have decreased by 22.3% and is now trading at $5.6040. View the best growth stocks for 2025 here. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) released its earnings results on Thursday, February, 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The company earned $0.01 million during the quarter, compared to analyst estimates of $0 million. Altimmune had a negative net margin of 199,076.92% and a negative trailing twelve-month return on equity of 55.81%. When did Altimmune's stock split? Shares of Altimmune reverse split on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Altimmune's major shareholders? Top institutional investors of Altimmune include Ameriprise Financial Inc. (7.39%), Vanguard Group Inc. (6.23%), Geode Capital Management LLC (2.33%) and Bellevue Group AG (1.33%). Insiders that own company stock include Vipin K Garg, David Drutz, Matthew Scott Harris, Wayne Pisano, M Scot Roberts and Diane Jorkasky. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY). Company Calendar Last Earnings2/27/2025Today3/14/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALT CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$20.83 High Stock Price Target$26.00 Low Stock Price Target$12.00 Potential Upside/Downside+255.8%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,450,000.00 Net Margins-199,076.92% Pretax Margin-199,076.92% Return on Equity-55.81% Return on Assets-50.60% Debt Debt-to-Equity RatioN/A Current Ratio16.87 Quick Ratio16.87 Sales & Book Value Annual Sales$20,000.00 Price / Sales22,545.85 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book2.13Miscellaneous Outstanding Shares77,014,000Free Float68,209,000Market Cap$450.92 million OptionableOptionable Beta0.87 10 Best Stocks to Own in 2025Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ALT) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMore important than tariffs for your stocksMost people are obsessed with Trump's on-again, off-again tariffs. Yes, the economic uncertainly is playin...Chaikin Analytics | SponsoredTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.